[go: up one dir, main page]

WO2012117334A8 - Modulateurs allostériques positifs de mglur5 pour l'utilisation dans le traitement du syndrome de phelan-mcdermid - Google Patents

Modulateurs allostériques positifs de mglur5 pour l'utilisation dans le traitement du syndrome de phelan-mcdermid Download PDF

Info

Publication number
WO2012117334A8
WO2012117334A8 PCT/IB2012/050894 IB2012050894W WO2012117334A8 WO 2012117334 A8 WO2012117334 A8 WO 2012117334A8 IB 2012050894 W IB2012050894 W IB 2012050894W WO 2012117334 A8 WO2012117334 A8 WO 2012117334A8
Authority
WO
WIPO (PCT)
Prior art keywords
positive allosteric
phelan
treatment
allosteric modulators
mcdermid syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/050894
Other languages
English (en)
Other versions
WO2012117334A1 (fr
Inventor
Alexander DITYATEV
Elena DVORETSKOVA
Carlo Sala
Chiara VERPELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consiglio Nazionale delle Richerche CNR
Fondazione Istituto Italiano di Tecnologia
Original Assignee
Consiglio Nazionale delle Richerche CNR
Fondazione Istituto Italiano di Tecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale delle Richerche CNR, Fondazione Istituto Italiano di Tecnologia filed Critical Consiglio Nazionale delle Richerche CNR
Publication of WO2012117334A1 publication Critical patent/WO2012117334A1/fr
Publication of WO2012117334A8 publication Critical patent/WO2012117334A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une nouvelle application thérapeutique pour des modulateurs allostériques positifs du récepteur métabotropique du glutamate mGluR5, notamment pour le traitement thérapeutique du syndrome de Phelan-McDermid provoqué par une délétion de 22qI3. Dans ce but, un modulateur allostérique positif préféré est le 3-cyano-N-(1,3-diphényl-1-H-pyrazol-5-yl)benzamide, dont l'abréviation est CDPPB.
PCT/IB2012/050894 2011-02-28 2012-02-27 Modulateurs allostériques positifs de mglur5 pour l'utilisation dans le traitement du syndrome de phelan-mcdermid Ceased WO2012117334A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITTO2011A000169 2011-02-28
ITTO2011A000169A IT1404270B1 (it) 2011-02-28 2011-02-28 Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid

Publications (2)

Publication Number Publication Date
WO2012117334A1 WO2012117334A1 (fr) 2012-09-07
WO2012117334A8 true WO2012117334A8 (fr) 2013-05-10

Family

ID=43976498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/050894 Ceased WO2012117334A1 (fr) 2011-02-28 2012-02-27 Modulateurs allostériques positifs de mglur5 pour l'utilisation dans le traitement du syndrome de phelan-mcdermid

Country Status (2)

Country Link
IT (1) IT1404270B1 (fr)
WO (1) WO2012117334A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835513B2 (en) 2013-06-28 2020-11-17 The Regents Of The University Of California Methods and treatments for the learning and memory deficits associated with Noonan syndrome
CN111601602B (zh) * 2017-10-27 2023-05-05 阿默制药有限公司 使用法呢基二苯并二氮杂酮治疗Phelan McDermid综合征的方法
CN113222975B (zh) * 2021-05-31 2023-04-07 湖北工业大学 一种基于改进U-net的高精度视网膜血管分割方法

Also Published As

Publication number Publication date
ITTO20110169A1 (it) 2012-08-29
WO2012117334A1 (fr) 2012-09-07
IT1404270B1 (it) 2013-11-15

Similar Documents

Publication Publication Date Title
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MY172156A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
WO2009100294A3 (fr) Dérivés d'amide en tant que modulateurs allostériques positifs et procédés d'utilisation associés
JO3454B1 (ar) تركيبات وطرق لتعديل مستقبلات فارنيسويد x
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
MY170713A (en) Treatment protocol of diabetes type 2
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
MX392150B (es) Moduladores de receptores canabinoides.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
UA110642C2 (uk) Композиція гербіциду і сафенеру
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
WO2009145996A3 (fr) Dérivés d’amide en tant que modulateurs allostériques positifs et procédés d’utilisation de ceux-ci
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
WO2010147830A3 (fr) Modulateurs aminothiazole de bêta-3-adrénorécepteur
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12713314

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12713314

Country of ref document: EP

Kind code of ref document: A1